Spelling suggestions: "subject:"histonedeacetylase"" "subject:"histondeacetylase""
1 |
Expression of Class I Histone Deacetylases in Insect CellsBryan, Erin E 30 May 2006 (has links)
"Histone deacetylases (HDACs) have become one of the leading areas of research for cancer, neurodegenerative diseases, diabetes, obesity, and inflammation. Although HDACs are currently expressible in mammalian cultures and yeast, it is important to explore other cost effective options. Here it is shown that class I HDACs are expressible in insect cells. As well as expressing full length domains for class I HDACs, predicted active domains have also been expressed. This information can be utilized in many areas for future research including identifying unique sites to allow development of specific inhibitors for each HDAC, and developing a better understanding of the specific role of each HDAC. "
|
2 |
Beyond induction of histone acetylation the multi-facets of the antineoplastic effect of HDAC inhibitors /Chen, Chang-Shi. January 2006 (has links)
Thesis (Ph. D.)--Ohio State University, 2006. / Full text release at OhioLINK's ETD Center delayed at author's request
|
3 |
Contribution à létude du rôle des déacétylases dhistones HDAC4 et HDAC8 dans la biologie des cellules de phénotype musculaire lisseGlénisson, Wendy 26 October 2007 (has links)
Les déacétylases dhistones (HDACs) constituent une famille denzymes identifiées initialement comme régulatrices du niveau dacétylation des histones, un processus important contrôlant la transcription génique. Comme leur nom lindique, il a longtemps été considéré que les seuls substrats des HDACs étaient les histones. Néanmoins, il est à présent démontré quelles peuvent aussi avoir dautres substrats nucléaires ou cytoplasmiques dont plusieurs facteurs de transcription et suppresseurs de tumeurs. Il a été montré que linhibition de lactivité des HDACs par des inhibiteurs globaux tels la trichostatine A (TSA) ou le suberoylanilide hydroxamique acide (SAHA) inhibe la croissance tumorale dans plusieurs modèles animaux. Linhibition des HDACs pourrait influencer tant les cellules tumorales que la néovascularisation de la tumeur (angiogenèse).
Au cours des précédentes années de notre doctorat, nous avons étudié lune des HDACs de classe I, HDAC8. Nous avons découvert que cette HDAC, principalement cytoplasmique, est spécifiquement exprimée par les cellules de phénotype musculaire lisse et sassocie avec lactine ? des muscles lisses (? SMA) (Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Waltregny D, De Leval L, Glenisson W, Ly Tran S, North BJ, Bellahcene A, Weidle U, Verdin E, Castronovo V. American Journal of Pathology, 2004 Aug;165(2):553-64. - Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. Glenisson W, Waltregny D, Tran SL, North BJ, Verdin E, Colige A, Castronovo V. FASEB Journal, 2005 Jun;19(8):966-8. - Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders. T. Weidel, G.J.J.M. van Eys, W. Glénisson, D. Waltregny, V. Castronovo, J.-M. Vanderwinden. Neurogastroenterology and motility, 2006, 18(7):526-38.). Nous avions suspecté que HDAC8 pourrait jouer un rôle important dans la biologie de la cellule musculaire, potentiellement via la déacétylation de protéines cytosquelettiques ou encore par régulation de la transcription de gènes impliqués dans la différenciation musculaire lisse. Ainsi afin détudier limpact potentiel de HDAC8 et dautres HDACs dans ce processus, nous avons utilisé une approche dARN interférence dans un modèle de différenciation myofibroblastique (un modèle de différenciation musculaire lisse senso stricto nétant pas disponible).
Les myofibroblastes (MFs) sont des cellules qui présentent des caractéristiques morphologiques et biochimiques intermédiaires entre des fibroblastes et des cellules musculaires lisses. La différenciation myofibroblastique, processus par lequel les fibroblastes aquièrent ces caractéristiques, peut être induite in vitro par des cytokines tel le TGF?1 (Transforming Growth Factor beta 1) mais sa régulation est encore mal connue. Les myofibroblastes jouent un rôle dans de multiples processus physiologiques, comme dans la cicatrisation, ainsi que dans des conditions pathologiques, comme dans linflammation chronique et le cancer. Plus précisément, les MFs pourraient jouer un rôle important dans le remodelage du stroma autour dun cancer, ce qui favoriserait la progression de certaines tumeurs (dont celles du colon).
De récentes études ont montré que la TSA empêche, dans des cultures de fibroblastes de rat, linduction par le TGF?1 de la fibrogenèse (synthèse de procollagène ?1(I) et ?1(III) et d?-SMA). Cette observation suggère limplication dHDACs dans la régulation de la différenciation myofibroblastique.
Nous avons donc entrepris didentifier la/les HDAC(s) régulant(s) spécifiquement(s) la différenciation myofibroblastique dans une culture primaire de fibroblastes de peau humaine grace à lutilisation de petits ARN interférants (siRNA) permettant de diminuer spécifiquement labondance de huit HDACs (HDAC1 à 8) tant au niveau de leur transcript que de leur protéine. Nous avons trouvé de manière reproductible que linduction de l?-SMA par le TGF?1 est bloquée par la transfection de siRNA spécifiques dHDAC4.
Afin détudier quels sont les autres aspects de la fibrogenèse qui sont régulés par HDAC4, ainsi que le rôle quHDAC4 pourrait jouer dans la régulation de la signalisation du TGF?1, nous avons étudié lexpression de trois inhibiteurs endogènes de la voie de signalisation du TGF?. De manière intéressante, la diminution dHDAC4 induite par les siRNA entraine une augmentation de lexpression de TGIF et de TGIF2 mais pas de Smad7. Dans létat actuel de nos connaissance, cette observation serait la première à indiquer que le niveau dexpression de TGIF et de TGIF2 puisse être régulé par une HDAC. (Histone deacetylase 4 is required for TGF?1-induced myofibroblastic differentiation, W. Glénisson, D. Waltregny, V. Castronovo, BBA Mol cell Research, 2007).
|
4 |
Analysis of human histone deacetylase 6 and its associated protein Ubl90Bertos, Nicholas R. January 2004 (has links)
Among mammalian histone deacetylases (HDACs) identified so far, HDAC6 is unique in that it possesses tandem deacetylase domains, as well as a carboxyl-terminal zinc finger motif implicated in ubiquitin binding. HDAC6 has also been demonstrated to deacetylate tubulin and thus potentially contribute to regulation of cell motility. Although HDAC6 has been reported to interact with a variety of nuclear factors, this enzyme is predominantly localized to the cytoplasm. / Here I show that the subcellular localization of human HDAC6 is governed by additional elements not present in orthologues of this protein from other species. Human HDAC6 contains a unique insertion of eight or ten repeats of a Ser/Glu-containing tetradecapeptide sequence, here termed the SE14-repeat domain, which is responsible for mediating the Leptomycin B-resistant cytoplasmic retention of human HDAC6. Human HDAC6 also contains a second functional leucine-rich nuclear export signal when compared to murine HDAC6, and a region near the amino terminus of human HDAC6 is capable of mediating nuclear import. / I have also identified a previously uncharacterized protein containing a ubiquitin-like domain, here termed Ubl90, as a novel binding partner for HDAC6. Interestingly, Ubl90 binds to the deacetylase domains of HDAC6, rather than to the carboxyl-terminal zinc finger motif previously implicated in ubiquitin association. Ubl90 also interacts with several class I HDACs (HDAC1, HDAC2 and HDAC8), although more weakly than with HDAC6. When Ubl90 is overexpressed, it leads to the redistribution of HDAC1 from a nuclear to a pancellular localization, although this does not affect HDAC1-dependent transcriptional repression in a transient transfection assay. Like HDAC6, Ubl90 is capable of repressing Runx2-mediated transcriptional activation, and, when overexpressed, it leads to cell cycle disturbances similar to those seen with HDAC6 overexpression. These results suggest that Ubl90 and HDAC6 interact functionally, as well as physically.
|
5 |
Therapeutic potential of demethylation agents and histone deaceytlase inhibitors in NK-cell lymphoma and leukemia /Kam, Kevin. January 2007 (has links)
Thesis (M. Med. Sc.)--University of Hong Kong, 2008.
|
6 |
Pharmacokinetics, pharmacodynamics, metabolism, transport, and resistance studies of a novel histone deacetylase inhibitor FK228 (FR901228, NSC630176)Xiao, Jin, January 2004 (has links)
Thesis (Ph. D.)--Ohio State University, 2004. / Title from first page of PDF file. Document formatted into pages; contains xix, 278 p.; also includes graphics (some col.) Includes bibliographical references (p. 256-278).
|
7 |
Expression of class I histone deacetylases in insect cellsBryan, Erin E. January 2006 (has links)
Thesis (M.S.) -- Worcester Polytechnic Institute. / Keywords: histone deacetylase. Includes bibliographical references (p.35-36).
|
8 |
The role of histone deacetylase 10 in y-globin gene regulation /Nimer, Sadeieh Abedaljaleel, January 2008 (has links)
Thesis (M.S.)--University of Texas at Dallas, 2008. / Includes vita. Non-Latin script record Includes bibliographical references (leaves 39-40)
|
9 |
Analysis of human histone deacetylase 6 and its associated protein Ubl90Bertos, Nicholas R. January 2004 (has links)
No description available.
|
10 |
The effect of histone deacetylase inhibitors on SRC and BCL2L1 gene expression and a potential role for phosphatases in their transcriptional repression2013 August 1900 (has links)
Histone Deacetylase Inhibitors (HDACi) are a new class of chemotherapeutics which have shown promise in pre-clinical and clinical settings. HDACi have been shown to act by re-programming gene expression, with the transcription of some genes such as p21WAF1 being activated, while others like SRC and BCL2L1 are repressed. The mechanism behind HDACi gene expression changes remains unknown; although it has been shown to involve a direct interaction with gene promoters.
Using a quantitative qRT-PCR approach, the effect of various HDACi on the transcription of p21WAF1, SRC and BCL2L1 was examined. TSA and apicidin led to an up regulation of p21WAF1 mRNA levels while c-Src and Bcl-xL mRNA levels were downregulated. Short c-Src mRNA transcripts were unaffected following TSA and apicidin treatments, despite the full length transcripts being repressed. Repression of full length c-Src and Bcl-xL mRNA transcripts was not seen following treatment with MS-275 and MGCD0103, although p21WAF1 mRNA expression was induced. ChIP experiments revealed that following HDACi treatment, histone acetylation levels and RNA Polymerase II occupancy increased in the promoter regions of both the SRC and BCL2L1 genes. RNA Polymerase II occupancy lasted less than 15 minutes in the 3’ regions of the gene following treatment with apicidin and TSA, but was more long-term following MS-275 and MGCD0103 treatment. The protein phosphatase inhibitor Calyculin A completely blocked HDACi mediated repression of c-Src and Bcl-xL mRNA, suggesting a role for protein phosphatases in the mechanism behind HDACi.
It is therefore hypothesized that HDACi work through at least two different mechanisms. Whether or not an HDACi leads to gene repression depends on its ability to disrupt an HDAC/protein phosphatase complex and not on their HDAC specificities. The disruption of the complex leads to the release of an active protein phosphatase. The released phosphatase can then presumably act on various factors changing a gene from an active to paused state, possibly through promoter proximal pausing. HDACi unable to disrupt this complex are unable to induce gene repression. Collectively, these studies highlight not only the complexity of HDACi mediated effects within the cell, but also present a new explanation behind HDACi mediated gene repression.
|
Page generated in 0.0377 seconds